Edition:
India

Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

3.41USD
19 Jan 2018
Change (% chg)

$-0.22 (-6.06%)
Prev Close
$3.63
Open
$3.61
Day's High
$3.63
Day's Low
$3.17
Volume
19,521
Avg. Vol
--
52-wk High
$6.35
52-wk Low
$2.06

Chart for

About

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent... (more)

Overall

Beta: 2.45
Market Cap(Mil.): $0.80
Shares Outstanding(Mil.): 0.20
Dividend: --
Yield (%): --

Financials

BRIEF-Aytu Bioscience Appoints David Green As CFO

* AYTU BIOSCIENCE ANNOUNCES APPOINTMENT OF DAVID GREEN AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Aytu Bioscience files for mixed shelf of upto $100 mln

* Aytu Bioscience Inc files for mixed shelf of upto $100 million - SEC Filing Source text: [http://bit.ly/2B3AW23] Further company coverage:

23 Nov 2017

BRIEF-Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system

* Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system for male infertility

07 Nov 2017

BRIEF-Aytu Bioscience CFO Gregory Gould resigns

* Aytu Bioscience Inc - ‍on October 26, 2017, Gregory A. Gould resigned as Chief Financial Officer​

28 Oct 2017

Earnings vs. Estimates